Mithila Zaheen

Dr. Mithila Zaheen


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2022 in European Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
RLRaymond Li
Raymond Li
KCKate Curtis
Kate Curtis
CVConnie Van
Connie Van
SZSyed Tabish Razi Zaidi
Syed Tabish Razi Zaidi
CYChin Yen Yeo
Chin Yen Yeo
Ronald CastelinoRonald Castelino
Ronald Castelino
Purpose: Adverse drug reaction (ADR) underreporting is highly prevalent across the world. This study aimed to identify factors associated with ADR reporting and map these to a behavioural change framework to help inform future interventions designed to improve ADR underreporting. Methods: A mixed methods survey was distributed to healthcare professionals at a tertiary hospital in Sydney, Australia. Quantitative data was analysed using logistic regression to identify factors that predict ADR reporting. Qualitative data was evaluated using content analysis. These were then integrated and mapped to the 14 domains within the Theoretical Domains Framework (TDF) to identify target areas relevant for improving ADR reporting. Results: One hundred thirty-three healthcare professionals completed the survey. Knowing how to report ADRs (OR 4.56, 95%CI 1.95–10.7), having been trained on ADR reporting (OR 2.72, 95%CI 1.29–5.77), and encountering ADRs as part of clinical practice (OR 10.3, 95%CI 3.59–29.4) were significant predictors of reporting an ADR. Content analysis identified three categories: modifying the ADR reporting process, enabling clinicians to report ADRs, and creating a positive ADR reporting culture. After data integration, the three target TDF domains were knowledge, environmental context/resources, and beliefs about consequences. Conclusion: Future interventions designed to improve ADR reporting should address these target domains to instigate behaviour change in healthcare professionals’ reporting of ADRs.

Verified
Journal Article
Open access
PDF file
MZMithila Zaheen
Mithila Zaheen
PPPatrick michael Pender
Patrick michael Pender
QDQuan Minh Dang
Quan Minh Dang
ESEva Sinha
Eva Sinha
JCJames J. H. Chong
James J. H. Chong
SZSarah Zaman
Sarah Zaman
Despite significant advancements in the primary and secondary prevention of cardiovascular disease, evidence shows a rising incidence of premature coronary artery disease (CAD) and myocardial infarction (MI) in patients aged < 50 years. This increase is linked to the growing prevalence of traditional cardiovascular risk factors among younger people, such as type 2 diabetes, hypertension, obesity, and hyperlipidaemia, which have led to a rise in atherosclerotic CAD. Additionally, emerging research points to the influence of less traditional risk factors, including chronic inflammation, autoimmune diseases, drug use, psychosocial factors, and novel biomarkers in the early onset of CAD. These factors collectively contribute to the rise in premature CAD, highlighting the need for improved prevention strategies and public health efforts focused on younger populations. In this review, we explore the aetiology, risk factor profile, role of novel biomarkers, and how each of these impact outcomes among younger patients with MI.

1 April 2025 in Medicina
Verified
Journal Article
Open access
PDF file
PPPatrick michael Pender
Patrick michael Pender
MZMithila Zaheen
Mithila Zaheen
QDQuan Minh Dang
Quan Minh Dang
VDViet Dang
Viet Dang
JXJames Xu
James Xu
SZSarah Zaman
Sarah Zaman
Spontaneous coronary artery dissection (SCAD) is an uncommon but significant cause of acute coronary syndrome (ACS), predominantly affecting younger women without traditional cardiovascular risk factors. SCAD is defined as a non-atherosclerotic, non-traumatic dissection of the coronary artery, leading to the formation of an intramural haematoma or intimal tear causing obstruction to blood flow and myocardial ischaemia. Unlike traditional atherosclerotic coronary artery disease, SCAD has unique pathophysiological mechanisms. SCAD is thought to arise secondary to a bleed and/or dissection within the arterial wall, linked to hormonal influences with potential triggers of physical or emotional stress and predisposition such as an underlying connective tissue disorder. Despite being increasingly recognised, SCAD remains underdiagnosed, and knowledge regarding SCAD epidemiology is limited. In addition, the impact of SCAD extends beyond the immediate cardiac event, encompassing psychological distress, the need for rehabilitation, and long-term surveillance. This has implications not just for the patient but also their family and the healthcare system. This narrative review summarises the current knowledge of SCAD epidemiology, including the affected population, its associated risk factors, and healthcare impact. By identifying current gaps in knowledge, this review aims to encourage targeted research, public awareness, and policy initiatives to improve outcomes for individuals affected by SCAD.

Verified
Journal Article
Open access
PDF file
MZMithila Zaheen
Mithila Zaheen
FFFardin Ferdous
Fardin Ferdous
AAAnjalee Thanuja Amarasekera
Anjalee Thanuja Amarasekera
JPJohannes Petutschnigg
Johannes Petutschnigg
FEFrank Edelmann
Frank Edelmann
TTTimothy C. Tan
Timothy C. Tan
Background/Objectives: Heart failure with preserved ejection fraction (HFpEF) is a complex clinical syndrome with limited therapeutic options. Mineralocorticoid receptor antagonists (MRAs) have been shown to improve clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF), but their use in patients with HFpEF remains controversial. The aim of this review is to evaluate whether the use of MRAs improves diastolic function, functional capacity, and quality of life in patients with HFpEF. Methods: A systematic literature search of scientific databases was performed to identify studies comparing the use of MRAs to placebo or no treatment in adult patients with HFpEF (2000–2024; English; PROSPERO registration CRD42022300783). Data were meta-analysed using a random-effects model for overall effect size measured as the standardised mean difference. Results: Pooled data revealed a significant benefit of MRA use compared to the control in decreasing E/e’ (SMD −0.21; 95% CI: −0.33 to −0.10, p = 0.00), with greater improvement seen with longer duration of treatment. A substantial reduction in systolic blood pressure (SMD −0.27; 95% CI: −0.53 to −0.02, p = 0.03) and diastolic blood pressure (SMD −0.18; 95% CI: −0.32 to −0.04, p = 0.01) was also noted. There was no significant difference in the 6 min walk distance, peak exercise capacity, or quality-of-life measures. Adverse events such as hyperkalaemia and worsening renal function were frequently reported in the MRA group. Conclusions: MRAs improve echocardiographic parameters of diastolic function and BP control; however, this did not translate into clinical outcomes of improved functional capacity or quality of life.